Wall Street Zen Upgrades GoodRx (NASDAQ:GDRX) to “Buy”

GoodRx (NASDAQ:GDRX) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

GDRX has been the subject of a number of other reports. TD Cowen decreased their price target on GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, November 10th. Citigroup decreased their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research report on Friday, January 9th. Mizuho dropped their target price on GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. UBS Group reaffirmed a “reduce” rating on shares of GoodRx in a report on Monday, January 5th. Finally, JPMorgan Chase & Co. dropped their price objective on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, GoodRx presently has an average rating of “Hold” and an average price target of $4.91.

GoodRx Stock Performance

NASDAQ GDRX opened at $2.68 on Friday. GoodRx has a 1 year low of $2.61 and a 1 year high of $5.81. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. The company has a market capitalization of $909.67 million, a PE ratio of 29.78, a P/E/G ratio of 1.02 and a beta of 1.45. The company has a fifty day moving average of $2.79 and a 200 day moving average of $3.75.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $196.03 million for the quarter, compared to analysts’ expectations of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.08 EPS. Research analysts forecast that GoodRx will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On GoodRx

Several institutional investors have recently bought and sold shares of the company. Woodstock Corp acquired a new position in shares of GoodRx during the fourth quarter valued at approximately $276,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of GoodRx during the fourth quarter worth approximately $65,000. PharVision Advisers LLC purchased a new stake in shares of GoodRx during the third quarter worth approximately $172,000. Utah Retirement Systems raised its stake in GoodRx by 79.0% in the 3rd quarter. Utah Retirement Systems now owns 292,212 shares of the company’s stock valued at $1,236,000 after purchasing an additional 128,958 shares during the last quarter. Finally, Quarry LP purchased a new position in GoodRx in the 3rd quarter valued at $33,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.